<DOC>
	<DOCNO>NCT00418080</DOCNO>
	<brief_summary>As clinical primary endpoint assess whether existed difference : 1 . PSA recurrence rate stratify accord treatment modality 2 . EGFR HER2/neu overexpression rate stratify accord treatment modality 3 . PSA recurrence rate stratify accord EGFR HER2/neu overexpression level . As secondary clinical endpoint assess whether existed difference : 1. prostate cancer-specific mortality accord treatment modality 2. prostate cancer-specific mortality stratify accord EGFR HER2/neu overexpression level . For purpose post treatment PSA-doubling time le 3 month find follow PSA recurrence consider surrogate endpoint prostate cancer-specific mortality Pre-clinical endpoint As pre-clinical endpoint assess whether exist difference efficacy rate Bicalutamide Gefitinib treatment primary tumor culture stratify high low EGFR HER2/Neu expression level . The evaluation efficacy rate treatment document compare difference drug IC50 value among group stratify EGFR HER2/Neu level .</brief_summary>
	<brief_title>Survival Outcomes Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Patients eligible histologically confirm adenocarcinoma prostate follow highrisk feature : ( 1 ) clinical stage T3a disease ( 2 ) Gleason sum 7 predominant component 4 ( i.e. , Gleason 4 + 3 = 7 ) ( 4 ) Gleason sum 8 , 9 10 . Prior hormonal therapy , Prior radiation , Prior investigational agent , Prior malignancy within last five year serious medical psychiatric condition illness would permit patient manage accord protocol exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>